Regorafenib in Patients With Refractory Primary Bone Tumors

NCT05395741 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Osteosarcoma
Ewing Sarcoma of Bone

Interventions

DRUG: Regorafenib

Sponsor

Institute of Mother and Child, Warsaw, Poland

Collaborators

[object Object]